Pseudovirus News and Research

RSS

Bivalent mRNA vaccine induces powerful antibody response to SARS-CoV-2 Omicron subvariants

Researchers discuss the development and efficacy of a bivalent mRNA vaccine against emerging variants such as BA.2.12.1, BA.4, or BA.5.

25 Jul 2022

Fourth dose of Pfizer mRNA COVID vaccine protective against variants and symptomatic infection

Researchers evaluate the efficacy of three- and four-dose regimens of a mRNA-based COVID-19 vaccine in reducing the risk of symptomatic infection.

20 Jul 2022

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Researchers reported mutations in SARS-CoV-2 Delta and Omicron variants of concern infection cases treated with neutralizing monoclonal antibodies.

20 Jul 2022

Study shows Omicron BA.4/5 infection triggers highly cross-reactive neutralizing antibodies

Researchers compared the levels of cross-reactive neutralizing antibodies elicited by SARS-CoV-2 Omicron BA.4 and BA.1 infections.

20 Jul 2022

The potential of circular RNA COVID-19 vaccines

A new MedComm study describes the potential use of circular ribonucleic acid COVID-19 vaccines.

17 Jul 2022

Study provides detailed understanding of SARS-CoV-2 Omicron sublineage antibody escape

A new study reveals the antibody-mediated neutralization of both current and emerging Omicron subvariants.

13 Jul 2022

Research assesses antigenic co-evolution of SARS-CoV-2 variants

In a recent study posted to the bioRxiv* preprint server, researchers analyzed antigenic variety across the significant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, like Omicron lineages.

8 Jul 2022

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

A recent study posted to the bioRxiv* preprint server supports using mosaic sarbecovirus receptor-binding domain (RBD)-nanoparticles to discover therapeutic pan-variant and pan-sarbecovirus monoclonal antibodies (mAbs) and to induce mAbs by vaccination.

30 Jun 2022

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A recent study by scientists at Celentyx Ltd, the University of Birmingham, and the University of Warwick and posted to the bioRxiv* preprint server illustrated a cell-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein attachment assay.

28 Jun 2022

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Researchers presented the PREVENT-19 phase 3 trial findings on the effectiveness of the NVX-CoV2373 adjuvanted, recombinant S nanoparticle vaccine.

27 Jun 2022

Antigenic differences between early SARS-CoV-2 variants

Researchers used antigenic cartography to quantify and visualize antigenic differences between multiple SARS‐CoV‐2 variants.

27 Jun 2022

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

A recent article posted to the bioRxiv* preprint server identified numerous efficacious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies from convalescent SARS-CoV-2 patients.

23 Jun 2022

Study finds traditional African drug inhibits growth of SARS-CoV-2 infection

Researchers evaluated the efficacy of PHELA, a traditional African drug, against SARS-CoV-2 in vitro.

21 Jun 2022

Type I interferons play crucial role in fending off SARS-CoV-2

Researchers investigated whether individuals with breakthrough infections of COVID-19 pneumonia demonstrated normal antibody responses to vaccinations and whether they harbored type I interferon-neutralizing auto-antibodies.

16 Jun 2022

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

In a recent study published in the journal PNAS, researchers demonstrated higher comparative efficacy of the intranasal (IN) route of coronavirus disease 2019 (COVID-19) vaccine administration versus intramuscular route in mice.

12 Jun 2022

Super-immunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain

A recent study published in Cell Reports reported the development of pan-sarbecovirus nanobodies (psNbs).

10 Jun 2022

The effect of Omicron breakthrough infection on the magnitude and breadth of serum neutralizing activity and memory B cells among BNT162b2 vaccinees

Researchers evaluated the impact of breakthrough infections with SARS-CoV-2 Omicron BA.1 sublineage on SARS-CoV-2 variants of concern neutralization and memory B lymphocytes formation among BNT162b2 vaccinees.

7 Jun 2022

De novo-designed mini-protein against SARS-CoV-2

Researchers characterized truncated forms of LCB1, a de novo-designed mini-protein, against SARS-CoV-2.

7 Jun 2022

Omicron lineage spike proteins use ACE2 receptors more efficiently

A recent study posted to the bioRxiv* preprint server demonstrated various traits, including the entry pathways and sensitivity to vaccination-elicited antibody responses by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants.

7 Jun 2022

HIV research enables knowledge transfer for improved COVID-19 response

Global virology and immunology networks that were originally developed for HIV vaccine research were rapidly adapted to study COVID-19.

31 May 2022

Pseudovirus News and Research

Bivalent mRNA vaccine induces powerful antibody response to SARS-CoV-2 Omicron subvariants

Fourth dose of Pfizer mRNA COVID vaccine protective against variants and symptomatic infection

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Study shows Omicron BA.4/5 infection triggers highly cross-reactive neutralizing antibodies

The potential of circular RNA COVID-19 vaccines

Study provides detailed understanding of SARS-CoV-2 Omicron sublineage antibody escape

Research assesses antigenic co-evolution of SARS-CoV-2 variants

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Antigenic differences between early SARS-CoV-2 variants

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

Study finds traditional African drug inhibits growth of SARS-CoV-2 infection

Type I interferons play crucial role in fending off SARS-CoV-2

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

Super-immunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain

The effect of Omicron breakthrough infection on the magnitude and breadth of serum neutralizing activity and memory B cells among BNT162b2 vaccinees

De novo-designed mini-protein against SARS-CoV-2

Omicron lineage spike proteins use ACE2 receptors more efficiently

HIV research enables knowledge transfer for improved COVID-19 response

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News